Dr. Marcus Butler
Dr. Marcus Butler
Dr. Marcus Butler
Immuno-oncology Translational Research Initiative (ACTION)


Immuno-oncology Translational Research Initiative (ACTION)

Dr. Marcus Butler is the Clinical Co-Leader of OICR’s Immuno-oncology Translational Research Initiative. His expertise includes clinical trials in a variety of immune therapies including adoptive T-cell therapy and checkpoint blockade.

Dr. Butler is the Clinical Head of the Immune Monitoring Team at the Princess Margaret Cancer Centre, where his group performs a wide variety of immunologic assays to examine the impact of therapies on immune phenotype and function.

Before joining the Princess Margaret Cancer Centre, he was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute.

Experience & Education
  • Medical Oncology Fellowship, Dana-Farber/Partners CancerCare
  • Internal Medicine Residency, Johns Hopkins Hospital
  • MD, Yale University School of Medicine
  • BA, Rice University
Current Affiliations
  • Co-Leader, Immuno-oncology Translational Research Initiative
  • Medical Oncology Disease Site Lead for Melanoma/Skin Oncology, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
  • Assistant Professor, Department of Medicine, University of Toronto
  • Associate Member, Department of Immunology, University of Toronto
Select Publications

See Dr. Butler’s recent publications on PubMed or Google Scholar.

Research Areas
Disease Areas
Opportunities to Collaborate

To collaborate with Dr. Butler, please contact him directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.